CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.
Looking for a particular CStone Pharmaceuticals employee's phone or email?
CStone Pharmaceuticals Questions
The CStone Pharmaceuticals annual revenue was $63.7 million in 2026.
Jason Yang is the CEO，President of R and D and Executive Director of the Board of CStone Pharmaceuticals.
120 people are employed at CStone Pharmaceuticals.
CStone Pharmaceuticals is based in Shanghai, Shanghai.
The NAICS codes for CStone Pharmaceuticals are [32541, 3254, 325, 32].
The SIC codes for CStone Pharmaceuticals are [28, 283].
Top CStone Pharmaceuticals Employees
-
11
-
45
-
Qingmei Shi
Associate Vice President at CStone Pharmaceuticals
Shanghai, China21 -
21
Related Companies
